


# ALK and ROS1 in NSCLC:

Optimising the  
continuum of care

13.00-14.30

Sunday 9 October 2016  
Oslo Auditorium, Bella Center  
Copenhagen, Denmark



## Chair's welcome

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**ALK and ROS1 in NSCLC: Optimising the continuum of care**'. The symposium will be held on **Sunday 9 October 2016** from **13.00-14.30**, during the ESMO 2016 Congress.

The rapid development of crizotinib and other ALK tyrosine kinase inhibitors (TKIs) allows patients with advanced ALK+ non-small cell lung cancer (NSCLC) to benefit from a long-term continuum of care with sequential ALK-targeted therapies.

During this symposium, our faculty will discuss the benefits of fast, quality-assured molecular testing in NSCLC. We will review the latest clinical outcomes that can be achieved for patients with advanced ALK+ or ROS1+ NSCLC and discuss strategies for maximising these outcomes, illustrated by real-world examples. We will also consider the spectrum of known mechanisms of resistance to crizotinib and other ALK TKIs, and the clinical challenges of resistance in this setting.

I look forward to welcoming you to Copenhagen and I hope you will join us for what promises to be an informative and engaging symposium.

Best regards,

**Tony Mok, Chair**

Professor of Clinical Oncology  
Li Shu Fun Medical Foundation,  
The Chinese University of Hong Kong, Hong Kong

## Programme

- 13.00 Welcome and introduction**  
**The importance of molecular testing in NSCLC**  
Tony Mok (Hong Kong)
- 13.15 ROS1+ NSCLC: Clinical data and experience**  
Alice Shaw (USA)
- 13.30 Panel discussion**  
All faculty
- 13.40 ALK+ NSCLC: How can we maximise clinical outcome today?**  
Sanjay Popat (UK)
- 14.00 Clinical consequences of resistance to ALK inhibitors**  
Alice Shaw (USA)
- 14.20 Panel discussion**  
All faculty
- 14.30 Meeting close**

**Light refreshments will be served prior to the symposium**



Merck KGaA, Darmstadt, Germany, and Pfizer co-promote XALKORI in the United States, Argentina, Canada, Japan, China, Turkey, and five European Union countries (France, Germany, Italy, Spain, and the United Kingdom).

This meeting is organised and funded by Pfizer Oncology  
© Pfizer Pharma GmbH. All rights reserved  
August 2016. PP-XLK-EUR-0177